Le Lézard
Classified in: Tourism and vacations, Health
Subjects: PDT, TRI

Lazarex: New FDA Guidance Means Hope For Cancer Patients


DANVILLE, Calif., Feb. 1, 2018 /PRNewswire-USNewswire/ -- The Food and Drug Administration has issued official guidance, giving the green light to reimburse patients for travel expenses to clinical trial sites. It allows all cancer patients access to potentially life-saving treatments.

Lazarex Cancer Foundation focuses on helping cancer patients identify their clinical trial options and serves as a resource to the patient and their families.

Many cancer patients who fail standard treatment but are eligible for clinical trials offering potentially life-saving drugs must decide between living expenses and hope. Why? Because clinical trial sites are often inconveniently located. Before now, reimbursement of travel expenses to get to those sites was considered coercion or "undue influence". Therefore, only those wealthy enough to pay for travel had access.

Lazarex Cancer Foundation brought this problem to the attention of the FDA. Lazarex is the only organization in the country helping patients find clinical trials and reimbursing them for travel expenses, and has been working to create an even playing field so ALL patients have access.

Lazarex Founder Dana Dornsife says, "If we don't have fully enrolled clinical trials with a diverse pool of patients, a cure is not possible. Clinical trials are the pathway to new treatments. But when you have only 3% of cancer patients enrolling in clinical trials and about 50% of clinical trials failing because they can't enroll enough patients, we have a broken system. That's why Lazarex took this issue to the FDA. We are pleased the FDA has issued this guidance."

The new guidance includes the following critical language: 
"FDA does not consider reimbursement for travel expenses to and from the clinical trial site and associated costs such as airfare, parking, and lodging to raise issues regarding undue influence."

Full FDA guidance language here.

INTERVIEW OPTIONS:

1) The patient
Brittani Powell, diagnosed with giant cell tumor at 12 years old, was given 6 months to live. Her mom found a clinical trial in Los Angeles, 300 miles from her Sacramento home, but the cost of travel to get there was a hardship and meant Brittani would have to drop out. Fortunately a nurse found Lazarex. The Foundation reimbursed Brittani's travel expenses, the trial saved Brittani's life, and the FDA approved the drug (denosumab) she was taking. Now 21, Brittani is a student at Sacramento State, studying to become a doctor. More patients here

2) Congressman Pete Sessions (R-TX) who, along with his colleagues and other stakeholders, worked for years on this issue to make the case to the FDA that reimbursement of a patient's direct expenses is not inducement but rather a recruitment incentive, enabling more patients to participate in cancer trials.

3) Congressman Jamie Raskin (D-MD) says: "This FDA guidance is a big step in helping to accelerate cancer detection, research, and care. Unfortunately for many cancer patients, travel costs are a significant barrier to participation in these life-saving trials. That is unacceptable. We should ensure that every cancer patient, regardless of his or her economic situation, should be able to participate."

SOURCE Lazarex Cancer Foundation


These press releases may also interest you

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
Closed System Transfer Devices Market in terms of revenue was estimated to be worth $1.1 billion in 2024 and is poised to reach $2.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. The...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....



News published on and distributed by: